69 Biotech Startups in UK to Watch in 2024
How do we build this list?
Last update to the database: May 26, 2024. See changelog.
Join 23,000+ founders, operators and investors.
Seedtable Score Learn how we calculate it here
We use raw data and human intuition to understand if a company is likely to outsource services like Hiring, Design, Development, etc.
company | score | funding | investors | employees | industries | biz model | city | contact |
---|---|---|---|---|---|---|---|---|
Antibody-Drug Conjugate specialist creating treatments for tough-to-treat cancers. |
$120M · Series B | TCG Crossover, Atlas Ventures, Brandon Capital | 11 to 50 | Health Tech, Biotech, Deep Tech, Pharma | B2B | London, UK | •••••••••••@pheontx.com | |
AI-driven intronization technology developer. |
$13M · Seed | Octopus Ventures, Acequia Capital, Redalpine | 1 to 10 | AI, Biotech | B2B, SaaS | London, UK | •••••••••••@expressionedits.com | |
Provider of single and multi-organ microphysiological systems. |
$21M · Series B | CN Innovations | 101 to 250 | Health Tech, Biotech | London, UK | •••••••••••@cn-bio.com | ||
Oophthalmic gene therapy company to treat blinding retinal illnesses. |
$120M · Series A | Syncona Partners LLP | 1 to 10 | Health Tech, Biotech | London, UK | •••••••••••@beacontx.com | ||
Portfolio of pharmaceutical research and discovery. |
$33M · Series C | Patient Square Capital, Rock Springs Capital, M&G Investments | 1 to 10 | Biotech, Pharma | London, UK | •••••••••••@apollotherapeutics.com | ||
Biomedical research discovery tool. |
$60M · Series B | ICONIQ Growth, Index Ventures, Pentech Ventures | 51 to 100 | Health Tech, AI, Biotech, Pharma | B2B, SaaS | London, UK | •••••••••••@causaly.com | |
AI vaccine algorithm developer. |
$11M · Series A | Hoxton Ventures, Merck Global Health Innovation Fund, Cherry Ventures | 1 to 10 | AI, Biotech | B2B, SaaS | London, UK | •••••••••••@baseimmune.co.uk | |
Discovery and development platform of superior microbial bioproducts. |
$6M · Series A | Pymwymic, Clean Growth Fund | 1 to 10 | Biotech | London, UK | •••••••••••@fungialert.com | ||
Neuroscience-driven AI platform. |
$2M · Seed | Rockmount Capital, Moonfire Ventures, UCL Technology Fund | 11 to 50 | AI, Biotech | B2B, SaaS | London, UK | •••••••••••@stanhopeai.com | |
Developer of non-biological affinity reagents to accelerate the production of cell and gene therapies. |
$8M · Series A | Mercia Asset Management | 11 to 50 | Health Tech, Biotech | London, UK | •••••••••••@mipdiscovery.com | ||
Preclinical stage treatment for geographic atrophy. |
$78M · Series A | Forbion Capital Partners, Gimv | 1 to 10 | Biotech | London, UK | •••••••••••@complementtx.com | ||
AI platform to map the human immune system. |
$14M · Series A | Molten Ventures, Life Extension Ventures | 11 to 50 | Health Tech, Biotech | London, UK | •••••••••••@imubiosciences.com | ||
Developer of sustainable plant-based pigments. |
$3M · Seed | PDS Ventures, Circular Innovation Fund, L'Oreal | 1 to 10 | Biotech, Manufacturing | B2C | London, UK | •••••••••••@sparxell.com | |
Platform to automate the clinical studies process. |
$12M · Series A | Playfair, Delin Ventures, 11.2 Capital | 11 to 50 | Health Tech, Biotech | B2B | London, UK | •••••••••••@umed.io | |
Patent-protected anti-inflammatory painkiller. |
$6M · Series A | ITV AdVentures | 1 to 10 | Biotech, Pharma | B2C | London, UK | •••••••••••@flarin.co.uk | |
Fully-automated cell manufacturing. |
$19M · Series A | Buckley Ventures, Wing Venture Capital, IQ Capital Partners | 11 to 50 | Biotech, Machine Learning | B2B | London, UK | •••••••••••@mytos.bio | |
Platform using deep learning on 3D molecular structures to develop treatments for harmful proteins. |
$50M · Series A | Khosla Ventures, General Catalyst | 1 to 10 | Health Tech, AI, Biotech, Data and Analytics | B2B | London, UK | •••••••••••@charmtx.com | |
Clinical trials platform. |
$18M · Series A | Valar Ventures, Creandum, Seedcamp | 11 to 50 | Health Tech, Biotech | B2B, SaaS | London, UK | •••••••••••@lindushealth.com | |
Sustainable corrosion inhibitors manufacturer. |
$1M · Seed | Oxford Innovation Finance, Waterspring Ventures, Development Bank of Wales | 1 to 10 | Biotech, Manufacturing | B2B | London, UK | •••••••••••@hexigone.com | |
Cell therapy firm specializing in developing treatments using advanced cellular technology. |
$45M · Series A | AlbionVC, Point72 Ventures | 101 to 250 | Health Tech, Edtech, Biotech, Manufacturing | B2B | London, UK | •••••••••••@quell-tx.com | |
User-owned genomics database platform. |
$20M · Series A | GEM Digital | 1 to 10 | Health Tech, Biotech | B2C | London, UK | •••••••••••@genomes.io | |
Gene silencing platform for the creation of programmable, allogeneic cell therapies. |
$16M · Seed | Mercia Asset Management, Calculus Capital, UK Innovation & Science Seed Fund | 1 to 10 | Health Tech, Biotech | London, UK | •••••••••••@laverocktx.com | ||
Platform specializing in developing new, high-yield tropical crop varieties and traits. |
$28M · Series B | Future Planet Capital | 11 to 50 | Agritech, Biotech, Deep Tech, Manufacturing | B2B | London, UK | •••••••••••@tropicbioscience.com | |
Biotechnology firm developing antiviral treatments for patients. |
$44M · Series C | Novo A/S, Andera Partners | 11 to 50 | Health Tech, Biotech, Pharma | B2B | London, UK | •••••••••••@reviral.co.uk | |
Manufacturing platform designed to help patients access lifesaving treatments. |
$30M · Series A | Kindred Capital, Octopus Ventures, Amadeus Capital | 1 to 10 | Health Tech, Biotech, Manufacturing | B2B | London, UK | •••••••••••@oribiotech.com | |
AI-powered drug testing platform. |
$1M · Pre Seed | Seedcamp, Episode 1 | 1 to 10 | AI, Biotech | London, UK | •••••••••••@sablebio.com | ||
Quantum simulation platform for drug discovery. |
$2M · Seed | Ascension Ventures, ACF Investors | 1 to 10 | Health Tech, Biotech | B2B, SaaS | London, UK | •••••••••••@kuano.ai | |
Pathfinder is developing a novel catheter based system that provides a better way for patients to receive haemodialysis for kidney failure. |
$11M · Series A | Business Growth Fund, Deepbridge Capital, Parkwalk Advisors | 1 to 10 | Health Tech, Biotech, Manufacturing | B2B | London, UK | •••••••••••@pathfindermed.com | |
Biotech lab spaces housed in shipping containers to make biotechnology accessible and affordable. |
$8M | Seventure Partners | 1 to 10 | Fintech, Biotech, Proptech & Real Estate, Manufacturing | B2B, SaaS | London, UK | •••••••••••@opencell.bio | |
Cancer treatment predictor software. |
$14M · Series A | Hoxton Ventures, Octopus Ventures, Fly Ventures | 11 to 50 | Health Tech, Biotech, Pharma | B2B | London, UK | •••••••••••@pearbio.com | |
Protein discovery research and manufacturing. |
$19M · Series A | SYSTEMIQ | 11 to 50 | Biotech, Deep Tech | London, UK | •••••••••••@basecamp-research.com | ||
Biotechnology firm focused on advancing RNA therapies. |
$10M | Y Combinator, Pi Campus | 11 to 50 | Health Tech, Biotech, Robotics, Manufacturing, Business Intelligence | B2B | London, UK | •••••••••••@sixfold.bio | |
Precision therapeutics discovery platform. |
$6M · Seed | Hoxton Ventures | 11 to 50 | Biotech | B2B | London, UK | •••••••••••@multiomic.uk | |
Drug discovery platform focused on developing small molecule inhibitors. |
$6M · Seed | Sofinnova Partners | 1 to 10 | Health Tech, Biotech, Deep Tech, Pharma | B2B | London, UK | •••••••••••@myricxpharma.com | |
At-home fertility treatment. |
$3M · Seed | Octopus Ventures, Calm/Storm Ventures, QVentures | 1 to 10 | Health Tech, Biotech | B2C | London, UK | •••••••••••@beafertility.com | |
Gynecological health company creating products and services for vaginal treatment. |
$5M · Seed | Khosla Ventures, Index Ventures, Kindred Capital | 11 to 50 | Health Tech, Biotech, Manufacturing, Ecommerce, Cannabis | B2C | London, UK | •••••••••••@yourdaye.com | |
Precision software for eye surgery. |
$8M · Seed | Redalpine | 1 to 10 | Health Tech, Biotech | London, UK | •••••••••••@hypervisionsurgical.com | ||
Immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer. |
$17M · Seed | AlbionVC, Boxer Capital, Syncona Partners LLP | 101 to 250 | Health Tech, Biotech | B2B | London, UK | •••••••••••@achillestx.com | |
3D human lung model developer. |
$2M · Seed | Pioneer Group, Mercia Asset Management, Midlands Engine Investment Fund | 11 to 50 | Biotech, Deep Tech | London, UK | •••••••••••@immuone.com | ||
Platform for developing materials that precisely target and remove harmful chemicals like PFAS from water. |
$3M · Seed | Kindred Capital, Verve Ventures | 11 to 50 | Climate Tech & Green Tech, Health Tech, Biotech, Deep Tech, Energy & Nuclear, Manufacturing | B2B | London, UK | •••••••••••@puraffinity.com | |
Biopharmaceutical company developing protein therapeutics with a machine learning-driven evolution engine. |
$3M · Seed | Atomico, Kindred Capital, Felicis Ventures | 51 to 100 | Health Tech, AI, Biotech, Deep Tech, Machine Learning, Robotics, Manufacturing | B2B | London, UK | •••••••••••@labgeni.us | |
Platform that industrializes photosynthesis to increase the global food supply. |
$4M · Seed | Business Growth Fund | 1 to 10 | Climate Tech & Green Tech, Foodtech, Biotech, Manufacturing | B2B | London, UK | •••••••••••@arborea.io | |
Computer simulation to understand drug-bacteria interactions. |
$5M · Seed | Hoxton Ventures, Sofinnova Partners | 1 to 10 | Biotech | London, UK | •••••••••••@biocortex.co.uk | ||
Building the future of food, starting with dairy. |
$2M · Seed | Entrepreneur First, Vorwerk Ventures, CPT Capital | 1 to 10 | Agritech, Foodtech, Biotech, Manufacturing | B2B, B2C | London, UK | •••••••••••@betterdairy.co.uk | |
Cultivated fat producer for the meat alternatives industry. |
$3M · Seed | BACKED VC, CPT Capital | 11 to 50 | Foodtech, Biotech, Manufacturing | B2B | London, UK | •••••••••••@hoxtonfarms.com | |
Immunotherapy for the treatment of cancer. |
$1M · Seed | Cancer Research Horizons, UK Innovation & Science Seed Fund | 11 to 50 | Biotech, Pharma | B2C | London, UK | •••••••••••@nk-io.com | |
Developer of cutting-edge DNA techniques to monitor biodiversity. |
$3M · Seed | SYSTEMIQ, BNP Paribas, Triple Point Ventures | 11 to 50 | Biotech | London, UK | •••••••••••@naturemetrics.co.uk | ||
Developer of drugs to treat respiratory diseases. |
$2M · Series A | Forbion Capital Partners, Versant Ventures, Imperial Innovations | 11 to 50 | Health Tech, Biotech | London, UK | •••••••••••@enterprisetherapeutics.com | ||
Platform helping the food sector reduce its carbon footprint. |
$4M | Octopus Ventures, Ascension Ventures, Metaplanet Holdings | 11 to 50 | Climate Tech & Green Tech, Health Tech, Agritech, Foodtech, Biotech, Deep Tech, Energy & Nuclear, Business Intelligence | B2B, SaaS | London, UK | •••••••••••@foodsteps.earth | |
Cell-free chemical manufacturer to produce bio-based alternatives |
$3M · Seed | Hoxton Ventures, Atomico, BACKED VC | 11 to 50 | Biotech | B2B | London, UK | •••••••••••@fabricnano.com | |
Immuno-oncology company treats cancer with antibodies. |
$2M · Series A | AlbionVC, Novartis Venture Fund, Epidarex Capital | 11 to 50 | Health Tech, Biotech, Deep Tech, Pharma, Manufacturing, Genetics | B2B | London, UK | •••••••••••@epsilogen.com | |
Epoch develops natural solutions to unnatural problems. First up: enzymes that transform plastics into circular chemicals. |
$3M · Pre Seed | Lowercarbon Capital, Ascension Ventures, BoxGroup | 11 to 50 | Biotech, Manufacturing | B2B | London, UK | •••••••••••@epochbiodesign.com | |
Digital-twin simulator. |
$3M · Pre Seed | Crane Venture Partners | 1 to 10 | Biotech, Supply Chain & Logistics | B2B | London, UK | •••••••••••@quaisr.io | |
We are a translational biophysics company focusing on the discovery of novel therapeutics against intrinsically disordered proteins. |
$2M | Hoxton Ventures, Bessemer Venture Partners | 11 to 50 | Health Tech, Biotech, Pharma, Manufacturing | B2B | London, UK | •••••••••••@peptone.io | |
Developer of novel Treg therapies to treat inflammatory disorders. |
$840k · Pre Seed | Deep Science Ventures, Wren Capital | 1 to10 | Health Tech, Biotech | B2C | London, UK | •••••••••••@bastion-tx.com | |
Short-duration psychedelic medicines developer for neuropsychiatric conditions. |
$40M · Series B | Leafy Tunnel, ATAI Life Sciences | 1 to 10 | Biotech, Pharma | B2C | Oxford, UK | •••••••••••@beckleypsytech.com | |
Developer of vaccines for the treatment of cancer. |
$16M · Seed | Octopus Ventures, Cancer Research Institute, Saras Capital | 1 to 10 | Health Tech, Biotech | B2C | Oxford, UK | •••••••••••@infinitopes.com | |
Clinical-stage research for alzheimer’s disease. |
$58M · Series A | EQT Partners, UCL Technology Fund, Brandon Capital | 1 to 10 | Health Tech, Biotech | Reading, UK | •••••••••••@astronautx.bio | ||
Bioinformatics discovery platform. |
$8M · Series A | Future Fund | 1 to 10 | Biotech, Data and Analytics | B2B, SaaS | Cambridge, UK | •••••••••••@plaquetec.com | |
Platform that helps businesses create optimal microbial communities. |
$1M · Pre Seed | Nucleus Capital | 1 to 10 | Agritech, Biotech, Business Intelligence | B2B, SaaS | London, UK | •••••••••••@concert.bio | |
Protein technology platform that finds new bispecific antibodies to treat cancer. |
$125k · Pre Seed | Hoxton Ventures, Y Combinator | 1 to 10 | Health Tech, Biotech | B2B, SaaS | London, UK | •••••••••••@liliumx.com | |
Biomedical CloudOS data platform. |
$120k · Seed | Eurazeo, Connect Ventures, Techstars | 51 to 100 | Health Tech, Biotech, Data and Analytics, Business Intelligence | B2B, SaaS | London, UK | •••••••••••@lifebit.ai | |
One lab management platform that brings people, equipment and data together - no matter where they are. |
$1M | Forward Partners | 11 to 50 | Health Tech, Biotech, Deep Tech | B2B, SaaS | London, UK | •••••••••••@clustermarket.com | |
Platform enhancing the efficiency, transparency, and diversity of clinical trials. |
$100k · Pre Seed | Atomico, Nina Capital | 11 to 50 | Health Tech, Biotech, Hiring and Recruitement, Data and Analytics, Community & Lifestyle, Business Intelligence | B2B, SaaS | London, UK | •••••••••••@neucruit.com | |
Developer of innovative treatment for muscle wasting disorders. |
$1M · Seed | Mankind Pharma | 1 to 10 | Biotech, Pharma | London, UK | •••••••••••@actimedtherapeutics.com | ||
Optical phenotyping technology and analytics optimize food production. |
$1M · Pre Seed | Seedcamp, Molten Ventures, MMC Ventures | 11 to 50 | Agritech, Foodtech, Biotech, Data and Analytics | B2B, SaaS | London, UK | •••••••••••@gardin.co.uk | |
Biotechnology platform accelerating cancer cell therapy discoveries with AI-driven TCR-antigen screening. |
$104k · Pre Seed | Atomico, Entrepreneur First | 1 to 10 | Health Tech, AI, Biotech, Deep Tech, Pharma, Data and Analytics | B2B | London, UK | •••••••••••@exogene.co.uk | |
Platform offering advanced targeted RNA, DNA, and CRISPR therapies. |
$125k · Pre Seed | Y Combinator | 1 to 10 | Health Tech, Biotech, Deep Tech | B2B | London, UK | •••••••••••@nuntiustx.com | |
Platform offering personalized digital health solutions for chronic gynecological conditions like endometriosis and PCOS. |
$253k · Seed | Y Combinator, Katapult Accelerator | 1 to 10 | Health Tech, Biotech, Deep Tech, Femtech, Ecommerce, ElderTech, Fertility | B2B | London, UK | •••••••••••@syronahealth.com |
Sign up to access our full database
Enter your email and get access to 18,000+ technology companies you can partner with.